1. Relapse

    Comments Leave a Comment

    1-15 of 63 1 2 3 4 5 »
    1. Mentioned In 63 Articles

    2. Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy

      Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy
      ...to three years. “Leukemia cells evolve in order to find ways to survive,” said Summers. “For the patients who relapse with CD22-positive leukemia, we are very pleased to now be able to offer a treatment option that will ...
      Read Full Article
    3. Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults

      Seattle Children's opens CD22 CAR T-cell immunotherapy trial for children and young adults
      ...to three years. "Leukemia cells evolve in order to find ways to survive," said Summers. "For the patients who relapse with CD22-positive leukemia, we are very pleased to now be able to offer a treatment option that will ...
      Read Full Article
    4. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

      The rationale for studying the combination of bevacizumab, irinotecan, and temozolomide (BIT) in neuroblastoma (NB) is based on the following: (i) vascular endothelial growth factor (VEGF) expression is associated with an aggressive phenotype, (ii) anti-VEGF antibody bevacizumab enhances irinotecan-mediated suppression of NB xenografts, (iii) bevacizumab safety has been established in pediatric phase I studies, and (iv) irinotecan + temozolomide (IT) is a standard salvage chemotherapy.
      Read Full Article
    5. 1-15 of 63 1 2 3 4 5 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about Relapse

    1. Although current treatments improve survival rates, patients suffer severe side effects and relapse tumors carry mutations that resist treatment.
      In Study Suggests Repurposing Anti-depressant Medication to Target Medulloblastoma
    2. We've been able to identify groups of patients who we consider very low risk for relapse and have been able to pull back on their therapy and prevent over treating.
      In The Medical Minute: Research Continues Improving Odds for Kids with Cancer
    3. Recent studies suggest that epigenetic modifications may contribute to the development of cancer progenitor cells that can induce drug resistance and the relapse of different types of cancer.
      In Cancer resistance may one day be treated with epigenetic drugs